Investigators at Brigham and Women's Hospital Describe Findings in Prostate Cancer (Cost-effectiveness Analysis of SBRT Versus IMRT for Low-risk Prostate Cancer)
By a News Reporter-Staff News Editor at Robotics & Machine Learning -- Researchers detail new data in Oncology. According to news originating from Boston, Massachusetts, by VerticalNews correspondents, research stated, "Intensity-modulated radiation therapy (IMRT) has been established as the standard external-beam modality in treating low-risk prostate cancer. Stereotactic body radiotherapy (SBRT) is a novel approach involving high-dose radiotherapy in 5 fractions."
Our news journalists obtained a quote from the research from Brigham and Women's Hospital, "This analysis compared their cost-effectiveness. A Markov model was constructed to delineate the health states after treatment with IMRT and SBRT. Disease, treatment, and toxicity data were extracted from the literature. Costs included both robotic (R-SBRT) and nonrobotic (NR-SBRT) reimbursement. Deterministic and probabilistic sensitivity analyses (PSA) were performed over a wide range of potential parameters. The quality-adjusted life expectancy after IMRT was slightly higher than after SBRT, because we assumed worse toxicity after SBRT. However, the incremental cost-effectiveness ratios (ICER) for IMRT over R-SBRT and NR-SBRT were $285,000 and $591,100/quality-adjusted life year (QALY), respectively. On sensitivity analysis, SBRT was almost always the cost-effective therapy, in which the ICER for IMRT was generally over $100,000/QALY. Reimbursement for R-SBRT versus NR-SBRT significantly influenced its ICER. Treatment efficacy, rectal toxicity and impotence, and the potential for unforeseen SBRT late effects were the most critical parameters in the model; when including these uncertain parameters in a PSA, SBRT was still most likely to be cost-effective at a willingness to pay of $ 100,000/QALY. SBRT clearly contained more value than IMRT for external-beam treatment."
According to the news editors, the research concluded: "Given the increasing prevalence of the disease and its superb convenience, intensive research should be performed on this novel modality, including the marginal benefit and cost of robotic treatment."
For more information on this research see: Cost-effectiveness Analysis of SBRT Versus IMRT for Low-risk Prostate Cancer. American Journal of Clinical Oncology-Cancer Clinical Trials, 2014;37(3):215-221. American Journal of Clinical Oncology-Cancer Clinical Trials can be contacted at: Lippincott Williams & Wilkins, 530 Walnut St, Philadelphia, PA 19106-3621, USA.
The news correspondents report that additional information may be obtained from D.J. Sher, Brigham & Women's Hospital, Boston, MA 02115, United States. Additional authors for this research include R.B. Parikh, S. Mays-Jackson and R.S. Punglia.
Keywords for this news article include: Boston, Oncology, Robotics, Radiotherapy, Massachusetts, United States, Prostate Cancer, Machine Learning, Prostatic Neoplasms, Emerging Technologies, North and Central America
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC